Medical Doctor Program year 2025 Reported 2020–2025 Source: CMS Open Payments, 2026 publication

Alex Schmidt

Pain Medicine Nashville, TN Medical Doctor

NPI 1669925756 CMS profile 4219744

3443 Dickerson Pike Ste 590, Nashville, TN 37207

Open in the dashboard

General payments

$10,002

289 records reported · program years 2020–2025

Research payments

$0

Paid to them · None reported · program years 2020–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Alex Schmidt of Nashville, TN is reported in the CMS Open Payments database as having received $10,002 across 289 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 85th percentile of Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,758 57
2024 General $2,856 78
2023 General $2,331 106
2022 General $487 26
2021 General $461 13
2020 General $2,110 9

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Alex Schmidt
  • Pain Medicine median
  • Middle half of Pain Medicine
  • National median

In program year 2025, general payments to Alex Schmidt were reported at $1,758. Among 1,144 Pain Medicine profiles paid that year, the median was $402 and the middle half received between $130 and $1,173.

Show as a table
Year Alex Schmidt Pain Medicine median Middle half National median
2019 $0 $409 $115–$1,311 $163
2020 $2,110 $214 $66–$666 $114
2021 $461 $299 $84–$899 $132
2022 $487 $335 $103–$1,149 $149
2023 $2,331 $376 $114–$1,228 $160
2024 $2,856 $387 $115–$1,173 $164
2025 $1,758 $402 $130–$1,173 $169

Breakdown

Who paid General payments · program years 2020–2025
  1. Abbott Laboratories $3,883 103 payments
  2. Medtronic USA, Inc. $1,711 3 payments
  3. AbbVie, Inc. $920 39 payments
  4. Boston Scientific Corporation $636 13 payments
  5. TerSera Therapeutics LLC $289 13 payments
  6. UCB, Inc. $287 19 payments
  7. Salix Pharmaceuticals, a division of Bausch Health US, LLC $284 14 payments
  8. Medtronic, Inc. $266 8 payments
  9. AstraZeneca Pharmaceuticals LP $221 11 payments
  10. Spinefrontier, Inc. $212 1 payment
  11. Other $1,293 65 payments

Every payment, record by record

What the payments were for General payments · program years 2020–2025
  1. Food and Beverage $8,274 286 payments
  2. Grant $1,667 1 payment
  3. Travel and Lodging $42 1 payment
  4. Education $20 1 payment
Products named General payments · program years 2020–2025
  1. PROCLAIM Neuromodulation $2,386 58 payments
  2. SYNCHROMED $1,667 1 payment
  3. PROCLAIM Structural Heart $568 7 payments
  4. BOTOX $562 22 payments
  5. OCTRODE $486 17 payments
  6. Prialt $289 13 payments
  7. GENERAL - PAIN MANAGEMENT $289 4 payments
  8. RELISTOR $284 14 payments
  9. Qutenza $274 12 payments
  10. QULIPTA $248 11 payments
  11. Other $3,848 167 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 10 drugs

Part D claims

267

Median for Physical Medicine and Rehabilitation: 276

Drug cost

$4,328

Median for Physical Medicine and Rehabilitation: $5,921

Branded share of claims

36.7%

Median for Physical Medicine and Rehabilitation: 11.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 52 $1,433
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 46 $1,118
Gabapentin Generic 39 $435
Oxycodone Hcl Generic 21 $311
Pregabalin Generic 24 $253
Tizanidine Hcl Generic 15 $230
Cephalexin Generic 29 $224
Baclofen Generic 15 $163
Celecoxib Generic 15 $126
Cyclobenzaprine Hcl Generic 11 $34

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 7,591 Part D prescribers listed as Physical Medicine and Rehabilitation; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 80 billing codes

Paid by Medicare

$374,730

Of which drugs: $123,921

Medicare patients

283

Average age 69

Services billed

50,927

163 women, 120 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Diabetes 34%
Depression 32%
Ischemic heart disease 30%
COPD 27%
Chronic kidney disease 23%
Heart failure 17%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, onabotulinumtoxina, 1 unit J0585 Office 13 7,510 $37,481
Injection, methylprednisolone acetate, 1 mg J1010 Office 107 13,121 $1,337
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 64 742 $559
Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml Q9966 Office 111 740 $215
Injection, ketorolac tromethamine, per 15 mg J1885 Office 28 308 $164
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 32 540 $48

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 21 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
BOTOX
  • AbbVie, Inc. $159
$159 — 7,510
Prialt
  • TerSera Therapeutics LLC $101
$101 — —
Qutenza
  • Averitas Pharma Inc. $61
$61 — —
Cimzia
  • UCB, Inc. $58
$58 — —
QULIPTA
  • AbbVie, Inc. $56
$56 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 21 in the dashboard with a free account

Records

289 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pain Medicine in Tennessee

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record